首页> 外文期刊>Advances in Experimental Medicine and Biology >Ovarian Cancer Biomarkers: Moving Forward in Early Detection
【24h】

Ovarian Cancer Biomarkers: Moving Forward in Early Detection

机译:卵巢癌生物标志物:早期检测前进

获取原文
获取原文并翻译 | 示例
       

摘要

Ovarian cancer is a silent cancer which rate survival mainly relays in early stage detection. The discovery of reliable ovarian cancer biomarkers plays a crucial role in the disease management and strongly impact in patient's prognosis and survival. Although having many limitations CA125 is a classical ovarian cancer biomarker, but current research using proteomic or metabolomic methodologies struggles to find alternative biomarkers, using non-invasive our relatively non-invasive sources such as urine, serum, plasma, tissue, ascites or exosomes. Metabolism and metabolites are key players in cancer biology and its importance in biomarkers discovery cannot be neglected. In this chapter we overview the state of art and the challenges facing the use and discovery of biomarkers and focus on ovarian cancer early detection.
机译:卵巢癌是一种沉默的癌症,其存活率主要在早期检测中继承。 可靠卵巢癌生物标志物的发现在疾病管理中起着至关重要的作用,对患者的预后和生存产生了强烈影响。 虽然具有许多局限性Ca125是一种典型的卵巢癌生物标志物,但使用蛋白质组学或代谢方法的目前的研究努力寻找替代生物标志物,使用非侵入我们的相对无侵入性来源,例如尿液,血清,血浆,组织,腹水或外源。 新陈代谢和代谢物是癌症生物学的关键参与者,其在生物标志物发现中的重要性不能被忽视。 在本章中,我们概述了艺术状态以及生物标志物使用和发现的挑战,并专注于卵巢癌早期检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号